Eli Lilly's 'Mounjaro PFS', known overseas as a game changer for obesity treatment, has been approved in Korea. In Korea, it has been approved as a treatment for diabetes.

Mounjaro is a synthetic peptide with a mechanism that can selectively bind to both the GIP and GLP-1 receptors for the first time in Korea. The Ministry of Food and Drug Safety (Ministry of Food and Drug Safety, Minister Oh Yu-Kyoung) has tested the content of 6 Mounjaro (2.5, 5, 7.5, 10, 12.5, 15mg/0.5ml) used as an adjuvant for diet and exercise therapy to control blood sugar in adult type 2 diabetic patients. It was confirmed on the 28th. This drug selectively binds to the GIP receptor and the GLP-1 receptor to induce insulin secr